Department of Biomolecular Sciences, University of Urbino, Campus Scientifico Enrico Mattei, Via Cà le Suore, 2/4, 61029, Urbino, PU, Italy.
Sci Rep. 2024 Jun 25;14(1):14610. doi: 10.1038/s41598-024-65623-y.
Extracellular vesicles (EVs) are promising natural nanocarriers for the delivery of therapeutic agents. As with any other kind of cell, red blood cells (RBCs) produce a limited number of EVs under physiological and pathological conditions. Thus, RBC-derived extracellular vesicles (RBCEVs) have been recently suggested as next-generation delivery systems for therapeutic purposes. In this paper, we show that thanks to their unique biological and physicochemical features, RBCs can be efficiently pre-loaded with several kinds of molecules and further used to generate RBCEVs. A physical vesiculation method, based on "soft extrusion", was developed, producing an extremely high yield of cargo-loaded RBCEV mimetics. The RBCEVs population has been deeply characterized according to the new guidelines MISEV2023, showing great homogeneity in terms of size, biological features, membrane architecture and cargo. In vitro preliminary results demonstrated that RBCEVs are abundantly internalized by cells and exert peculiar biological effects. Indeed, efficient loading and delivery of miR-210 by RBCEVs to HUVEC has been proven, as well as the inhibition of a known mRNA target. Of note, the bench-scale process can be scaled-up and translated into clinics. In conclusion, this investigation could open the way to a new biomimetic platform for RNA-based therapies and/or other therapeutic cargoes useful in several diseases.
细胞外囊泡(EVs)是有前途的天然纳米载体,可用于输送治疗剂。与任何其他类型的细胞一样,在生理和病理条件下,红细胞(RBCs)产生的 EV 数量有限。因此,最近有人提出 RBC 衍生的细胞外囊泡(RBCEVs)是用于治疗目的的下一代递药系统。在本文中,我们证明了由于其独特的生物学和物理化学特性,RBC 可以有效地被多种分子预加载,并进一步用于生成 RBCEVs。我们开发了一种基于“软挤压”的物理囊泡化方法,可产生极高产量的载药 RBCEV 模拟物。根据新的 MISEV2023 指南对 RBCEV 群体进行了深入表征,在大小、生物学特性、膜结构和载药方面表现出高度均一性。体外初步结果表明,RBCEVs 被细胞大量内化,并发挥独特的生物学效应。事实上,已经证明 RBCEVs 可以有效地将 miR-210 加载并递送至 HUVEC,并抑制已知的 mRNA 靶标。值得注意的是,该台架规模的工艺可以放大并转化为临床应用。总之,这项研究为基于 RNA 的治疗和/或其他在多种疾病中有用的治疗性载药的新型仿生平台开辟了道路。